03-21-05

PATENT

MAR 1 8 2005

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RADIA Re Application of:

Brenda F. Baker, et al.

Confirmation No.: 5950

**Application No.: 10/700,930** 

**DOCKET NO.: ISIS-5326** 

Group Art Unit: 1645

Filing Date: November 4, 2003

**Examiner: Not Yet Assigned** 

For: MODIFIED OLIGONUCLEOTIDES FOR USE IN RNA INTERFERENCE

EXPRESS MAIL LABEL NO: EV325730131US DATE OF DEPOSIT: Warch 18, 2005

EV325730131US

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).

In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in § 1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or

(AV

	before the mailing date of a first Office Action after the filing of request for
	continued examination under § 1.114, no additional fee is required.
	In accordance with § 1.97(c), this Information Disclosure Statement is being
	filed after the period set forth in § 1.97(b) above but before the mailing date of
	either a Final Action under § 1.116 or a Notice of Allowance under § 1.311, or
	before an action that otherwise closes prosecution in the application, therefore:
	Certification in Accordance with § 1.97(e) is attached; or
	The fee of \$180.00 as set forth in § 1.17(p) is attached.
	In accordance with § 1.97(d), this Information Disclosure Statement is being
	filed after the mailing date of either a Final Action under § 1.113 or a Notice
	of Allowance under § 1.311 but before, or simultaneously with, the payment
	of the Issue Fee, therefore included are: Certification in Accordance with §
	1.97(e); and the submission fee of <u>\$180.00</u> as set forth in § 1.17(p).
	Copies of reference numbers listed on the attached Form PTO-1449 are
	enclosed herewith.
$\boxtimes$	A copy of reference number 253 on the attached Form PTO 1449 is not
	required to be submitted pursuant to waiver of 37 CFR § 1.98(a)(2)(i).
	Copies of references - are not being submitted because
	they were previously cited by or submitted to the U.S. Patent and
	Trademark Office in patent application number , filed for
	which a claim for priority under 35 U.S.C. § 120 has been made in the
	instant application.
The 1	relevance of those listed references which are not in the English language is as
follo	ns.

**DOCKET NO.: ISIS-5326** 

- 3 -

**PATENT** 

There are no listed references which are not in the English language.

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

Date: March 26, 2005

John A. Harrelson, Jr. Registration No. 42,637

WOODCOCK WASHBURN LLP One Liberty Place - 46th Floor

Philadelphia, PA 19103 Telephone: (215) 568-3100 Facsimile: (215) 568-3439

© 2005 WW

			:				
Fo	rm PT	O-1449 Modifie	d	Docket No. ISIS-5326	Applica 10/700	ation No.	
	Cite	tent and Publications of by Applicant al sheets if necessary		Applicant Brenda F. Baker, et	al.		
U.S. Department of Commerce Patent and Trademark Office				Filing Date November 4, 2003	Group 1645		
				Confirmation No. 5950			
		<b>U.</b> :	S. PATEN	T DOCUMENTS	•		
Examiner Initial		Document No.	Date	Name		Class	Subclass
*	252	2002/0091736 41	06/27/02	Common et al		125	155

Examiner Initial		Document No.	Date	Name	Class	Subclass
*	253	2002/0081736 A1	06/27/02	Conroy, et al.	435	455

## FOREIGN PATENT DOCUMENTS

Examiner	Document No.	Date	Country	Translation	
Initial				YES	NO
EXAMINER			DATE CONSIDERED		

<sup>\*</sup> Cited on the PCT Written Opinion dated March 7, 2005 (PCT/US03/35146).